San Diego, California-based Mast Therapeutics Inc. is pinning its hopes on its vasodilating AIR001 program for heart failure following the second Phase III failure for its sickle cell disease candidate vepoloxamer.
Mast’s share price on the NYSE plummeted to $0.11 on the morning of Sept. 21 following the announcement made late...
Welcome to Scrip
Create an account to read this article
Already a subscriber?